Related Experiment Video
Updated: May 30, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
[Selective serotonin reuptake inhibitors (SSRI) and osteoporosis]
Anne-Catherine Fétique-Will1, Thierry Chevalley, René Rizzoli
1Service de psychiatrie générale, Département de santé mentale et de psychiatrie, HUG, 121I Genève 14. anne-catherine.will-fetique@hcuge.ch
Abstract:
Selective serotonin reuptake inhibitors (SSRI) represent the first-line treatment of depression. Several studies demonstrate that use of therapeutical doses of SSRI is associated with a decreased bone mineral density (BMD) and an increased risk of fracture. Mechanisms of action of SSRI on bone tissue are not totally clarified. These treatments would be associated with an increased risk of falls and would also have a direct effect on bone metabolism. Regarding proofs existing of the implication of SSRI on osteoporosis, while waiting for larger-scale prospective studies, it appears reasonable that practitioners assess bone loss within risk groups of patients treated with SSRI.
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Dose-Response Relationship: Selectivity and Specificity
Osteoclasts in Bone Remodeling